BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.
BioNTech buys Biotheus and its Keytruda rival for $950m
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued share capital and up to $150 million in potential milestone payments.
BioNTech to buy Chinese biotech firm to boost oncology strategy
German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect tumor cells in patients - Anadolu Ajansı
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company believed that the Biotheus drug “has the potential to set a new standard of care in multiple oncology indications”.
BioNTech to Acquire Biotheus to Boost Oncology Strategy
Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational
BioNTech to Acquire Biotheus in $950 Million Deal
BioNTech has agreed to acquire biotechnology company Biotheus for $800 million up front and up to $150 million in milestone payments. The German developer of RNA vaccines and immunotherapies said Wednesday that the acquisition builds on its oncology ...
FierceBiotech9h
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
STAT1h
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
DPA International on MSN1h
Germany's BioNTech to buy Chinese firm with promising cancer drug
Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...
BioNTech To Buy Biotheus In Upfront Payment Of $800 Mln
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
Seeking Alpha on MSN1h
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay ...
BioNTech SE ADR falls Tuesday, underperforms market
The BioNTech SE ADR BNTX slid 2.22% to $106.32 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 and Dow Jones ...
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
Deutsche Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...